Tradestie Institutional Equity Comparison Engine
ABIG vs BOLD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BOLD Overall Edge
BOLD Captures Institutional Edge (2โ0 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Boundless Bio, Inc. Common Stock (BOLD) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, ABIG trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus BOLD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ABIG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BOLD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ABIG N/M vs BOLD N/M Fwd P/E
Growth & Margin Winner
BOLD
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner
BOLD
1Y +1.3% vs +101.7% ยท 52W Pos 41% vs 62%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ABIG
NASDAQ
Argent Large Cap ETF
Institutional Equity
$31.73
-3.67% 1D
Market Cap
N/A
1M Return
-9.65%
1Y Return
+1.31%
Forward P/E
N/M
Unified AI Score
46.8 / 100
HOLD
Tech 36.0
Fund 48.0
Flow 50.0
Mom 60.0
BOLD
NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap
$56.2M
1M Return
-4.92%
1Y Return
+101.74%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 25.0
Fund 50.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ABIG +1.31%
BOLD +101.74%
Spread: +100.15 pp (BOLD Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ABIG TTM Op. Margin: N/A
BOLD TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABIG vs BOLD. Trailing 12-month operating profitability (ABIG N/A vs BOLD 0.0%) and valuation multiples (ABIG N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABIG | BOLD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $56.2M | Larger Scale | BOLD |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +0.0% | Higher Growth | BOLD |
| Operating Margin (TTM) Profitability | N/A | 0.0% | Higher Margin | BOLD |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | BOLD |
| Return on Equity (ROE) Capital Efficiency | N/A | -64.6% | Higher ROE | BOLD |
| 52-Week Range Position Momentum | 41% ($28โ$36) | 62% ($1โ$3) | Stronger Trend | BOLD |
| Beta / 30D Volatility Risk Regime | 1.00ฮฒ ยท 22% Vol | -0.08ฮฒ ยท 28% Vol | Lower Realized Risk | ABIG |
| Unified Institutional Score Composite Signal | 46.8 / 100 (HOLD) | 36.8 / 100 (SELL) | Higher Composite | ABIG |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ABIG vs BOLD Buy Guide
ABIG
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
BOLD
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ABIG nor BOLD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.